Factor V Leiden Is Associated with Repeated and Recurrent Unexplained Fetal Losses

Summary

Activated protein C resistance (APCR) is responsible for most cases of familial thrombosis. The factor V missense mutation Arg506>Gln (FV Leiden) has been recognized as the commonest cause of this condition. Recently, it has been suggested that APCR is associated with second trimester fetal loss. We investigated the distribution of FV Leiden in a sample (n = 43) of Caucasian women with a history of two or more unexplained fetal losses. A group (n = 118) of parous women with uneventful pregnancies from the same ethnical background served as control. We found the mutation in 7 cases (16.28%) and 5 controls (4.24%; p = 0.011). A statistically significant difference between women with only early fetal loss vs those with late events (p = 0.04) was observed. Our data demonstrate a strong association between FV Leiden and fetal loss. Furthermore, they indicate that late events are more common in these patients.

• References

• 1 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de RondeH, van derVelden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 2 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg 506 Gin mutation in factor Va. Lancet 1994; 334: 1361-1362
• 3 Rosendaal FR, Koster T, Vandenbrouke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508
• 4 Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614
• 5 Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 094-100
• 6 Preston FE, Rosendaal FR, Walker ID, Briët E, Bemtorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van derMeer FJM. Increased fetal loss in women with heritable thromphilia. Lancet 1996; 348: 913-916
• 7 Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1995; 92: 489-490
• 8 Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
• 9 Rees DC, Cox M, Clegg JB. World distribution of FV Leiden. Lancet 1995; 346: 1133-1134
• 10 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 11 Dekker GA, Vries JIP, Doelitzsch PM, Huijgens PC, von BlombergBME, Jakobs C, van GeijnHP. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048
• 12 Out HJ, Bruinse HW, Christiaens GCML, van VlietM, de GrootPG, Nieuwenhuis HK, Derksen RHWM. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26-32
• 13 Lyall F, Greer IA. Pre-eclampsia: a multifaceted vascular disorder of pregnancy. J Hypert 1994; 12: 1339-1345
• 14 Zöller B, Svensson PJ, HE X, Dahlbäck B. Identification of the same Factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated Protein C. J Clin Invest 1994; 94: 2521-2524
• 15 Rai RS, Regan L, Chitolie A, Donald JG, Cohen H. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol 1996; 103: 842-844
• 16 Cumming AM, Tait RC, Fildes S, Yong A, Kenney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-727